Home›Lactulose Solution Usp 10 G15 Ml›Lactulose Solution Usp 10 G15 Ml + Neomycin

Does Lactulose Solution Usp 10 G15 Ml Interact with Neomycin?

CDI records a moderate classification for Lactulose Solution Usp 10 G15 Ml and Neomycin. The stored summary is: Elimination of colonic bacteria by neomycin may interfere with lactulose degradation and prevent acidification of colonic contents. Patient status should be closely monitored. The mechanism involves elimination of colonic bacteria may interfere with lactulose degradation. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Stored CDI classification
Moderate
Lactulose Solution Usp 10 G15 Ml Class
Osmotic Laxative
Management
Confirm exact products with your pharmacist
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

Elimination of colonic bacteria may interfere with lactulose degradation

What To Tell Your Doctor or Pharmacist

If you are taking Lactulose Solution Usp 10 G15 Ml and your doctor is considering prescribing Neomycin (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Lactulose Solution Usp 10 G15 Ml(Lactulose Solution)+💊 Neomycin(Tresaderm)

Severity & Interaction Details

🟡
moderate
Stored CDI classification: moderate
A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.
Severity scale
MinorContra
On record
Yes
Drug A class
Osmotic Laxative
Drug B class
—
Source
NLP:lactulose solution usp, 10 g/15 ml

What this means in plain English

Elimination of colonic bacteria by neomycin may interfere with lactulose degradation and prevent acidification of colonic contents. Patient status should be closely monitored.

About Lactulose Solution Usp 10 G15 Ml and Neomycin

Lactulose Solution Usp 10 G15 Ml is an Osmotic Laxative. Neomycin is also sold under the brand name Tresaderm.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:lactulose solution usp, 10 g/15 ml

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Lactulose Solution Usp 10 G15 Ml and Neomycin against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations